当前位置: X-MOL 学术Lancet › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study.
The Lancet ( IF 98.4 ) Pub Date : 2020-01-11 , DOI: 10.1016/s0140-6736(19)32545-0
Ola Olén 1 , Rune Erichsen 2 , Michael C Sachs 3 , Lars Pedersen 4 , Jonas Halfvarson 5 , Johan Askling 3 , Anders Ekbom 3 , Henrik Toft Sørensen 4 , Jonas F Ludvigsson 6
Affiliation  

BACKGROUND Ulcerative colitis (UC) is a risk factor for colorectal cancer (CRC). However, available studies reflect older treatment and surveillance paradigms, and most have assessed risks for incident CRC without taking surveillance and lead-time bias into account, such as by assessing CRC incidence by tumour stage, or stage-adjusted mortality from CRC. We aimed to compare both overall and country-specific risks of CRC mortality and incident CRC among patients with UC. METHODS In this population-based cohort study of 96 447 patients with UC in Denmark (n=32 919) and Sweden (n=63 528), patients were followed up for CRC incidence and CRC mortality between Jan 1, 1969, and Dec 31, 2017, and compared with matched reference individuals from the general population (n=949 207). Patients with UC were selected from national registers and included in the analysis if they had two or more records with a relevant International Classification of Disease in the patient register (in the country in question) or one such record plus a colorectal biopsy report with a morphology code suggestive of inflammatory bowel disease. For every patient with UC, we selected matched reference individuals from the total population registers of Denmark and Sweden, who were matched for sex, age, birth year, and place of residence. We used Cox regression to compute hazard ratios (HRs) for incident CRC, and for CRC mortality, taking tumour stage into account. FINDINGS During follow-up, we observed 1336 incident CRCs in the UC cohort (1·29 per 1000 person-years) and 9544 incident CRCs in reference individuals (0·82 per 1000 person-years; HR 1·66, 95% CI 1·57-1·76). In the UC cohort, 639 patients died from CRC (0·55 per 1000 person-years), compared with 4451 reference individuals (0·38 per 1000 person-years; HR 1·59, 95% CI 1·46-1·72) during the same time period. The CRC stage distribution in people with UC was less advanced (p<0·0001) than in matched reference individuals, but taking tumour stage into account, patients with UC and CRC remained at increased risk of CRC death (HR 1·54, 95% CI 1·33-1·78). The excess risks declined over calendar periods: during the last 5 years of follow-up (2013-17, Sweden only), the HR for incident CRC in people with UC was 1·38 (95% CI 1·20-1·60, or one additional case per 1058 patients with UC per 5 years) and the HR for death from CRC was 1·25 (95% CI 1·03-1·51, or one additional case per 3041 patients with UC per 5 years). INTERPRETATION Compared with those without UC, individuals with UC are at increased risk of developing CRC, are diagnosed with less advanced CRC, and are at increased risk of dying from CRC, although these excess risks have declined substantially over time. There still seems to be room for improvement in international surveillance guidelines. FUNDING The Swedish Medical Society, Karolinska Institutet, Stockholm County Council, Swedish Research Council, Swedish Foundation for Strategic Research, Independent Research Fund Denmark, Forte Foundation, Swedish Cancer Foundation.

中文翻译:

溃疡性结肠炎中的结直肠癌:一项基于斯堪的纳维亚人口的队列研究。

背景技术溃疡性结肠炎(UC)是结直肠癌(CRC)的危险因素。但是,现有的研究反映了较旧的治疗和监测范例,并且大多数研究都在未考虑监测和前置时间偏倚的情况下评估了发生CRC的风险,例如通过按肿瘤分期评估CRC发生率或由CRC进行分期调整的死亡率。我们旨在比较UC患者的CRC死亡率和发生CRC的总体风险和特定国家风险。方法在这项基于人群的队列研究中,丹麦(n = 32919)和瑞典(n = 63528)对96447例UC患者进行了随访,对1969年1月1日至12月31日期间的CRC发生率和CRC死亡率进行了随访。 ,2017年,并与来自一般人群的匹配参考个人进行比较(n = 949 207)。如果UC患者有两个或更多记录(在相关国家/地区,在相关患者病历中具有相关的国际疾病分类),或其中一个这样的记录加上具有形态学的结直肠活检报告,则将其纳入国家分析提示炎症性肠病的代码。对于每位UC患者,我们从丹麦和瑞典的总人口登记册中选择了匹配的参考个体,这些参考个体的性别,年龄,出生年份和居住地均匹配。我们使用Cox回归来计算事件CRC和CRC死亡率的危险比(HRs),并考虑了肿瘤的分期。结果在随访过程中,我们观察到UC队列中1336例CRC(每1000人年1·29)和参考个体中9544例CRC(每1000人年0·82; HR 1·66,95%CI 1·57-1·76)。在UC队列中,有639例死于CRC的患者(0·55每1000人-年),而4451个参考个体(0·38每1000人-年; HR 1·59,95%CI 1·46-1· 72)。UC患者的CRC分期分布不及相匹配的参考个体(p <0·0001),但考虑到肿瘤分期,UC和CRC患者的CRC死亡风险仍然较高(HR 1·54、95 %CI 1·33-1·78)。在日历期间内,额外风险有所下降:在随访的最后5年(仅2013-17年,仅瑞典),UC患者发生CRC的HR为1·38(95%CI 1·20-1·60) ,或者每5年每1058例UC患者增加1例),CRC死亡的HR为1·25(95%CI 1·03-1·51,或者每5年每3041例UC患者增加1例) 。解释与没有UC的人相比,患有UC的人罹患CRC的风险增加,被诊断为患有晚期CRC的人,并且死于CRC的风险增加,尽管这些额外的风险随着时间的推移已大大降低。国际监测准则似乎仍有改进的余地。资金瑞典医学会,卡罗林斯卡研究所,斯德哥尔摩县议会,瑞典研究理事会,瑞典战略研究基金会,丹麦独立研究基金会,Forte基金会,瑞典癌症基金会。国际监测准则似乎仍有改进的余地。资金瑞典医学会,卡罗林斯卡研究所,斯德哥尔摩县议会,瑞典研究理事会,瑞典战略研究基金会,丹麦独立研究基金会,Forte基金会,瑞典癌症基金会。国际监测准则似乎仍有改进的余地。资金瑞典医学会,卡罗林斯卡研究所,斯德哥尔摩县议会,瑞典研究理事会,瑞典战略研究基金会,丹麦独立研究基金会,Forte基金会,瑞典癌症基金会。
更新日期:2020-01-10
down
wechat
bug